Company announces first patient dosed in pivotal Phase 3 trial of apraglutide for the treatment of short bowel syndrome

Phase 3 STARS trial is the first trial of this next-generation, long-acting GLP-2 analog, designed to exclusively evaluate a once-weekly dosing interval and to take into account remnant bowel anatomy and individual caloric needs during weaning patients off of parenteral support.

Source:

Biospace Inc.